2seventy bio, Bristol Myers Squibb Discontinue Enrollment In Phase 3 KarMMa-9 Study
Portfolio Pulse from Benzinga Newsdesk
2seventy bio and Bristol Myers Squibb have decided to discontinue enrollment in the Phase 3 KarMMa-9 study due to improvements in the NDMM treatment landscape and a review of the business case.
September 25, 2024 | 10:03 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Bristol Myers Squibb, in collaboration with 2seventy bio, has discontinued enrollment in the Phase 3 KarMMa-9 study, reflecting strategic adjustments in response to the evolving NDMM treatment landscape.
While the discontinuation may reflect strategic realignment, Bristol Myers Squibb's diverse portfolio may mitigate significant short-term impact on its stock price.
CONFIDENCE 85
IMPORTANCE 50
RELEVANCE 60
NEGATIVE IMPACT
2seventy bio has decided to discontinue enrollment in the Phase 3 KarMMa-9 study, which may impact its future product pipeline and investor sentiment.
The decision to halt enrollment in a Phase 3 study suggests potential setbacks in product development, which could negatively affect investor sentiment and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80